Repligen Q3 revenue beats estimates on higher demand; lifts outlook
Overview
US bioprocessing tech firm's Q3 revenue rose 11%, beating analyst expectations
Q3 adjusted EPS beat analyst expectations
Company closed BioLife acquisition and raised FY26 revenue guidance
Outlook
Repligen raises FY26 revenue guidance to $844 mln-$852 mln, up 14.5%-15.5%
Company expects FY26 organic revenue growth of 12%-13%
Repligen forecasts FY26 adjusted EPS of $2.05-$2.09
Result Drivers
PORTFOLIO STRENGTH - Co said revenue growth was driven by continued strength across its diversified portfolio
IMPROVING DEMAND - Co said end-market demand continues to improve, with healthy trends in consumables and services and a growing capital equipment order book
BIOLIFE ACQUISITION - Co said completion of BioLife acquisition strengthens position in cell therapy market and expands portfolio
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Beat | $209 mln | $206.62 mln (18 Analysts) |
Q3 Adjusted EPS | Beat | $0.53 | $0.46 (17 Analysts) |
Q3 Adjusted Operating Income | $33.30 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 17 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Repligen Corporation is $200.00, about 11% above its October 26 closing price of $180.17
The stock recently traded at 71 times the next 12-month earnings vs. a P/E of 60 three months ago
Reuters Recommended Reads
Oct 27 - Nautilus Biotechnology Q3 revenue beats
Oct 26 - China's WuXi AppTec nine-month revenue rises on chemistry segment growth; lifts 2026 outlook
Oct 27 - Novartis slightly misses Q3 net sales estimates, but tops core EPS view
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)